TheCRE.com
CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments
Reg Week Archives
Data Access
Data Quality
Regulation by Litigation
Regulation by Information
Regulation by Appropriation
Special Projects
CRE Watch List
Emerging Regulatory Issues
Litigation
OMB Papers
Abstracts and Reviews
Guest Column
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Interactive Public Docket
Electronic Regulatory Reform
Consumer Response Service
Interactive Public Docket
Docket Service
Docket Service
Featured Items on TheCRE.com

National Archives Interview March 2009: Centralized Regulatory Review NOW LIVE
GW 30th Anniversary OIRA
History of Centralized Regulatory Review
Policy Entrepreneurs
The Coming of the Regulatory Budget

®:
CRE's Regulatory Action
of the Week


FDA Reschedules Public Hearings on Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products
The U.S. Food and Drug Administration has rescheduled a 2-day public hearing to obtain input on four draft guidance documents relating to the regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps). The public hearing will be held on September 12 and 13, 2016, from 9 a.m. to 5 p.m. The hearing on September 13 may be extended or end early depending on the number of speakers scheduled. Persons (including FDA employees) seeking to view the hearing via a live Webcast are not required to register. Persons (including FDA employees) seeking to attend in person or to attend and speak at the public hearing must register by June 1, 2016.

  • Click here to read the Federal Register notice of this action, which provides more details.
  •    


    disclaimer
    Copyright Notice The Center for Regulatory Effectiveness [Copyright © 2007]. All right reserved.